Veracyte Overview
- Year Founded
-
2006
- Status
-
Public
- Employees
-
755
- Stock Symbol
-
VCYT
- Investments
-
6
- Share Price
-
$24.30
- (As of Friday Closing)
Veracyte General Information
Description
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
Contact Information
Website
www.veracyte.comCorporate Office
- 6000 Shoreline Court
- Suite 300
- South San Francisco, CA 94080
- United States
Corporate Office
- 6000 Shoreline Court
- Suite 300
- South San Francisco, CA 94080
- United States
Veracyte Stock Performance
As of 13-Nov-2026, Veracyte’s stock price is $24.30. Its current market cap is $1.96B with 80.7M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $24.30 | $24.63 | $21.91 - $60.91 | $1.96B | 80.7M | 1.79M | $1.59 |
Veracyte Financials Summary
As of 30-Sep-2026, Veracyte has a trailing 12-month revenue of $582M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 3,256,064 | 3,001,995 | 2,814,600 | 1,820,585 |
| Revenue | 581,782 | 517,145 | 445,764 | 361,051 |
| EBITDA | 124,390 | 76,978 | 38,051 | (56,753) |
| Net Income | 126,849 | 66,353 | 24,138 | (74,404) |
| Total Assets | 1,573,256 | 1,406,019 | 1,300,035 | 1,114,906 |
| Total Debt | 40,736 | 39,654 | 50,737 | 12,630 |
Veracyte Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Veracyte Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Veracyte Comparisons
Industry
Financing
Details
Veracyte Competitors (16)
One of Veracyte’s 16 competitors is Foundation Medicine, a Formerly VC-backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Foundation Medicine | Formerly VC-backed | Boston, MA | ||||
| Natus Medical | Private Equity-Backed | Middleton, WI | ||||
| GeneCast Biotechnology | Private Equity-Backed | Wuxi, China | ||||
| Decipher Urologic Cancers | Formerly VC-backed | San Diego, CA | ||||
| Myriad Genetics | Corporation | Salt Lake City, UT |
Veracyte Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Veracyte Patents
Veracyte Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026169900-A1 | Biomarkers in pre-operative prostate cancer | Pending | 07-Feb-2025 | ||
| WO-2026050182-A1 | Prognosis and treatment of metastatic prostate cancer | Pending | 28-Aug-2024 | ||
| WO-2026010877-A1 | Methods for tumor fraction analysis using spectral analysis methods | Pending | 01-Jul-2024 | ||
| WO-2025251039-A1 | Methods and systems for estimation of molecular residual disease, tumor mutational burden, and clonal hematopoiesis | Pending | 31-May-2024 | ||
| GB-2645114-A | Methods and systems of classifying tumor tissue samples | Pending | 16-Jun-2023 | C12Q1/6886 |
Veracyte Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Veracyte Investments & Acquisitions (6)
Veracyte’s most recent deal was a Merger/Acquisition with Convergent Genomics for . The deal was made on 14-Sep-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Convergent Genomics | 14-Sep-2026 | Merger/Acquisition | Diagnostic Equipment | ||
| C2i Genomics | 05-Feb-2024 | Merger/Acquisition | Decision/Risk Analysis | ||
| Qiagen Marseille | 02-Aug-2021 | Merger/Acquisition | Diagnostic Equipment | ||
| Decipher Urologic Cancers | 12-Mar-2021 | Merger/Acquisition | Diagnostic Equipment | ||
| NanoString Technologies (License of nCounter Diagnostic Assets and Rights) | 03-Dec-2019 | Corporate Asset Purchase | Buildings and Property |
Veracyte ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
23.37 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Healthcare
Industry
of 590
Rank
Percentile
Medical Devices
Subindustry
of 209
Rank
Percentile
Veracyte Exits (1)
Veracyte’s most recent exit was on 02-Aug-2021 from Qiagen Marseille. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Qiagen Marseille | 02-Aug-2021 | Completed |
|
Veracyte Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Convergent Genomics | San Francisco, CA | 2014 | |
| Decipher Urologic Cancers | San Diego, CA | 2008 |
Veracyte FAQs
-
When was Veracyte founded?
Veracyte was founded in 2006.
-
Where is Veracyte headquartered?
Veracyte is headquartered in South San Francisco, CA.
-
What is the size of Veracyte?
Veracyte has 755 total employees.
-
What industry is Veracyte in?
Veracyte’s primary industry is Diagnostic Equipment.
-
Is Veracyte a private or public company?
Veracyte is a Public company.
-
What is Veracyte’s stock symbol?
The ticker symbol for Veracyte is VCYT.
-
What is the current stock price of Veracyte?
As of 13-Nov-2026 the stock price of Veracyte is $24.30.
-
What is the current market cap of Veracyte?
The current market capitalization of Veracyte is $1.96B.
-
What is Veracyte’s current revenue?
The trailing twelve month revenue for Veracyte is $582M.
-
Who are Veracyte’s competitors?
Foundation Medicine, Natus Medical, GeneCast Biotechnology, Decipher Urologic Cancers, and Myriad Genetics are some of the 16 competitors of Veracyte.
-
What is Veracyte’s annual earnings per share (EPS)?
Veracyte’s EPS for 12 months was $1.59.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
